Ticker

Shares of Promis Neurosciences (NASDAQ: PMN - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the four research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 12-month price

Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer's disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from…

Extends cash runway into 2028 Proceeds expected to enable completion of ProMIS' landmark  Phase 1b AD study and support execution of key clinical milestones Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026 CAMBRIDGE, Massachusetts , Jan. 30, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology…

Shares of Promis Neurosciences (NASDAQ: PMN - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the four research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease